found that a T lymphocyte transcriptional gene signature was prognostic in DLBCL and PTL (cutoffs, at the bottom 17.7 percentile and 20 percentile, respectively) (61), and also confirmed the adverse prognostic effects of lower percentages of CD3+CD4+ and CD3+CD8+ TILs in PTL patients using mIHC (61). The gene discussed is CD8A; the disease is diffuse large B-cell lymphoma.